Takeda fleshes out CNS pact with peptide drugmaker, setting aside $3.5B in future milestones

One of a suite of drugmakers looking to reinvest in the neuroscience space, Takeda has been aggressive in signing on new partners to help build up its pipeline in that space. But sometimes the best partner is the one you already have.